论文部分内容阅读
目的探讨希罗达为基本药物的同步放化疗治疗胃癌根治术后患者的临床效果.方法选取于2013年1月~2014年2月在我院接受根治术治疗的胃癌患者52例为研究对象,随机分为对照组和观察组,对照组采取常规药物对症治疗,观察组患者采取以希罗达为基药的同步放化疗进行治疗,比较两组的疗效.结果经治疗后观察组的疗效较为理想,其中疗效为显著的有18例、有效的有7例、无效的有1例,治疗的总有效率为96.15%;对照组26例患者经过治疗后,其疗效为显著、有效、无效,患者人数依次为10例、7例、9例,治疗的总有效率为65.38%,观察组的疗效明显高于对照组,组间疗效比较差异有统计学意义(P〈0.05).结论希罗达联合放化疗治疗胃癌根治术后患者具有良好的临床效果,可以提高患者的生存率以及降低复发率和毒副反应. “,”Objective To investigate the basic drug Xeloda clinical effects of concurrent radiotherapy and chemotherapy for gastric cancer surgery. Methods In January 2013- February 2014 patients with gastric cancer in our hospital treated 52 patients with radical surgery for the study were randomly divided into a control group and observation group and control group taking conventional medication and symptomatic treatment,observation patients taking Xeloda-based drugs to concurrent chemoradiation therapy,therapeutic effects were compared. Results After treatment effect observed after treatment ideal group for which there is a significant treatment effect 18 cases,there are seven cases effectively,there is one case of ineffective treatment effective rate of 96.15% of the total; 26 patients in the control group after after treatment,the treatment effect was significant,effective and ineffective,the number of patients were 10 cases,seven cases,nine cases,the treatment of the total effective rate 65.38%,the treatment effect observed group was significantly higher in treatment effect between the two groups comparison with a significant difference,P〈0.05. Conclusion Xeloda combined radiotherapy and chemotherapy for gastric cancer patients with good clinical results,can improve the survival rate and reduce the relapse rate and toxicity.